Search Browse Earnings

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Nasdaq:LIXT

Pharmaceutical Preparations·BOCA RATON, FL

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

LIXTE BIOTECHNOLOGY HOLDINGS, INC. — SlamSEC

Revenue

$200,000

FY 2015

Adj. EBITDA

-$5.1M

-2545.1% margin

FY 2024

Net Income

-$5.1M

-2543.5% margin

FY 2024

EPS (Diluted)

-$2.66

FY 2024

Stock Price

$3.11

-4.0%

2026-03-13

52W Range

$0.64 – $6.26

P/E Ratio

-1.2x

Market Cap

$17.7M

Cash

$5.4M

FY 2023

Total Debt

—

Net Cash

$5.4M

FY 2015

Enterprise Value

$12.4M

Debt / EBITDA

1.1x

FY 2015

EV / EBITDA

-2.4x

Employees

—

CEO

Pursglove Geordan Garrett

CFO

Stazzone Peter